ORIGINAL RESEARCH PAPER
Volume - 12 | Issue - 07 | July - 2023 | PRINT ISSN No. 2277 - 8179 | DOI : 10.36106/ijsr
INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH

ASSOCIATION BETWEEN HYPERTHYROIDISM AND CARDIOVASCULAR RISK: A SYSTEMATIC REVIEW AND META-ANALYSIS OF COHORT STUDIES

General Medicine

Ankita Kashyap Head of Department (Medicine), Maha Mrityunjay Hospital, Azamgarh, U.P., India

Krishna Nand Sharma Managing Director, Virtued Academy International, Azamgarh, U.P., India

ABSTRACT

Thyrotoxicosis may result from the thyroid secreting and releasing abnormally high levels of thyroid hormone during hyperthyroidism. The analysis can be guided by clinical findings and subsequently supported by biochemical testing, imaging methods including ultrasonography, and measurements of radioactive iodine take-up. Among the various bodily parts damaged by this ailment are the integument, exterior muscles, and resistive, ophthalmic, conceptual, gastrointestinal, and cardiovascular frameworks. By treating cardiovascular symptoms early on in addition to hyperthyroidism, large cardiovascular events can be prevented. The presence of hyperthyroidism as another risk factor for cardiovascular occasions is as yet questionable. Unmistakable and subclinical hyperthyroidism adds to ischemic coronary illness, stroke, cardiovascular degeneration, and passing. Tried to decide if it is related with an expanded risk of Studies on the relationship among hyperthyroidism and cardiovascular occasions were checked on utilizing the Bar Remedy and Embase datasets. Cardiovascular illness risk was delegated high or low in light of past ailments like history of coronary, cerebral, or fringe conduit sickness. Cardiovascular breakdown; atrial fibrillation; diabetes mellitus; or constant kidney infection this meta-analysis included 37 cohort studies. In addition, the occurrence of IHD in members with asymptomatic hyperthyroidism was altogether expanded in the low CVD risk bunch. These connections were more clear in the gathering of people who had passable CVD however no major CVD.

KEYWORDS

Hyperthyroidism, Cardiovascular Risk, Meta-Analysis, Cohort Studies

INTRODUCTION

Hyperthyroidism is the term used to describe an unnaturally high union or potential release of thyroid chemicals from the thyroid organ. Fundamental clinical side effects of thyrotoxicosis, a clinical condition brought about by an overabundance of the thyroid synthetic in the tissues, are available (Agbaht K, 2014). We look at the reasons for hyperthyroidism, clinical signs and their understanding, and numerous dosing choices for the most widely recognized hyperthyroidism, including Thyroid Storm (TS).

A clinical problem known as thyrotoxicosis, a type of hyper thyroidism, is described by strangely high tissue levels of thyroid chemical. Graves' illness, harmful multinodular goiter, and risky adenoma are the three primary drivers. Radioactive iodine (RAI) has been utilized to treat hyperthyroidism for more than 70 years. As per the rules of the American Thyroid Affiliation, RAI treatment is unequivocally suggested as one of three significant medicines for patients with hyperthyroidism in straight to the point Graves' sickness.

If well established thyroid chemo substitution needs and prompt objectives of hyperthyroidism are less significant than full oversight of hyperthyroidism, evasion of clinical mediation, and conceivable symptoms of underground bug thyroid meds, RAI treatment is liked (Berta E, 2019). Broad utilization of RAI treatment has raised worries about its penchant to cause leukemia and malignant growth. RAI treatment for thyroid cancer5-7 and for hyperthyroidism has been connected to a higher risk of the potentially hazardous neoplasm's that may develop, despite the fact that numerous studies have found no links.

One of the primary objective organs of thyroid chemicals is the cardiovascular system, and increased or decreased TSH levels might negatively affect the cardiovascular system (Jabbar A, 2017). According to a few research, subclinical hypothyroidism increases cardiovascular risk factors such as altered lipid profiles, insulin resistance, oxidative pressure, increased vascular solidity, and endothelial breakage. Additionally, subclinical hyperthyroidism manifested in the cardiovascular system in a variety of ways, including increased pulse, left ventricular mass, vulnerability to endothelial damage, and left ventricular diastolic dysfunction, which can alter the morphology and function of the heart(Kim HJ, 2020).

METHODS

In accordance with a predetermined protocol, we oversaw the methodological research and the meta-analysis, and we summarized the findings in light of the PRISMA declaration.

Search strategy

From their inception to February 28, 2020, written searches were conducted on the Bar Prescription and Embase data repositories. Additionally evaluated were the meta-studies, linked articles, and contemporary research' reference lists.

Clinical subject headings (like "hyperthyroidism," "thyroid illnesses," "thyroid chemicals," "myocardial ischemia," "cardiovascular breakdown," "stroke," "cerebrum ischemia," "mortality," and "cardiovascular illness") and text words (like "subclinical thyroid," "thyroid infections," "coronary illness," and "ischemic coronary illness" were used to guide the search process. Additionally, we looked for dark writing on the Open Dark website.

Statistical analyses

To process an outline HR and its 95% confidence interval, the review explicitly maximally changed HR was used. Heterogeneity was estimated utilizing the I2 estimation between lower, center and 25% to half, particularly at values over 50 (importance low, directional and high heterogeneity, separately).

The Higgins I2 technique was utilized to concentrate on heterogeneity. A fixed-impact model was utilized as the included studies were named not extremely heterogeneous when I2 was under half. On the off chance that the I2 was more noteworthy than half, the included studies were decided to have critical heterogeneity and the arbitrary impacts model was applied.

To explore and understand the causes of substantial heterogeneity, we ran responsiveness and subgroup analyses. We investigated the association between age-specific CV outcomes (take status, adequate versus inadequate regions) and hyperthyroidism.

Basic circumstances that might expand the risk of cardiovascular sickness, like coronary, cerebrum, or fringe corridor contaminations, broadened cardiomyopathy, cardiovascular breakdown, atrial fibrillation (AF), diabetes mellitus, or constant kidney infection A background marked by disease was viewed as having a place with the high-risk CVD bunch. The low cardiovascular risk group reported no infections that could increase the risk of cardiovascular disease.

RESULTS

Characteristics of included studies

An analysis choice stream frame is displayed in Fig. 1. A sum of 15,118 studies was at first perceived, of which 13,075 stayed subsequent to eliminating copy references.



Figure 1: Flowchart for selecting and screening studies.

Table 1 presents the study's characteristics. A total of 1,515,004 participants were chosen, and 124,484 of them had hyperthyroidism. The sample numbers of participants in these studies ranged from 258 to 1,239,441. There are 15 individuals with a typical age of 65 and over, and 22 individuals with a typical age of 65. 11 studies altogether uncovered that those with earlier illnesses were bound to foster cardiovascular infection (CVD). 26 studies used participants from the general public and were population-based studies. They were referred to be low CVD risk. The Newcastle-Ottawa Scale evaluation tool determined that all included studies were of moderately great quality, with values ranging from 6 to 9.

Table 2: Subgroup analysis of fundamental hyperthyroidism and risk of cardiovascular occasions

Subgroup	Pooled HR (95% CI)	I2, %	No. of studies
Ischemic heart disease			
Age group			
<65 yr	1.22 (1.02–1.18)	0	5
≥65 yr	NA	-	-
CVD risk group			
Increase	NA	-	-
Decrease	1.22 (1.02–1.18)	0	5
Stroke			
Age group			
<65 yr	1.27 (1.05–1.87)	45.3	11
≥65 yr	0.75(0.19–3.35)	-	2
CVD risk group			
Increase (with A-fib)	3.04 (0.22–30.38)	50.6	4
Decrease	1.28 (1.15–2.34)	45.4	9
Heart failure			
Age group			
<65 yr	1.34 (0.82–3.25)	80.5	3
≥65 yr	NA	-	-
CVD risk group			
Increase	NA	-	-
Decrease	1.34 (0.82–3.25)	80.5	3
CV mortality			
Age group			
<65 yr	1.25 (0.82–2.54)	85.3	7

Table 1: Fundamental features of current meta-analyses include cohort studies

Study	Country	Study population	Classification of hyperthyroidism	Mean or median age	No. of total subjects	No. of hyperthyroid subjects	CV outcome
Agbaht K, Gullu S. (2014)	Korea	communal residence	Overt	Overt: 37.4 Control: 57.4	1,327,552	48,032	IHD and stroke
Berta E, (2019)	England	communal residence	Overt	Overt:37±18 Control: 37±18	30,836	3,278	IHD, stroke, and HF
Jabbar A,. (2017)	Finland	communal residence	Subclinical	Subclinical: 7.9±15.4 Control: 40.4±24.7	4,322	207	IHD and stroke
Kim HJ, (2020)	Finland	communal residence	Overt	50 (46–52)	35,470	5,237	IHD, stroke, HF, and CV mortality
Kwon H, (2018)	United States	communal residence	Overt	Overt: <60 years Control: <60 years	84,067	2,402	CV mortality
la Cour JL, (2015)	Sweden	communal residence	Overt	Overt: 52.2 Control: 50.2	24,815	23,328	CV mortality
Langen VL, (2018)	United States	communal residence	Overt, subclinical	Overt: 65.6±4.7 Subclinical: 65.3±6.8 Control: 65.4±6.8	12,248	Overt: 305 Subclinical: 267	IHD and stroke
Lillevang-Johansen M, (2019)	United Kingdom	communal residence	Subclinical	74.4±0.3	752	28	CV mortality
Martin SS, (2017)	France	High CVD risk (people with A-fib)	Overt	Overt:82±15 Control: 79±15	7,851	252	Stroke
Page MJ, (2021)	China	High CVD risk (hemodialysis for diabetes)	Subclinical	Subclinical: 78.4±15.6 Control: 47.7±14.6	1,224	63	IHD
Ross DS, (2016)	Denmark	communal residence	Overt	Overt:52.8±15.4 Control:52.0±15.3	34,651	3,000	Stroke
Ryodi E, (2018)	Taiwan	Community dwelling	Overt	Overt: 50.8±15.4 Control: 52.4±15.6	79,573	25,707	Stroke
Berlin JA, (2008)	China	High CVD risk (people with A-fib)	Overt	Overt: 66.2±2.6 Control: 68.5±2.2	358	73	Stroke
Wartofsky L. (2012)	Germany	High CVD risk (hemodialysis for diabetes)	Subclinical	Subclinical: 55.8±6.8 Control: 56.4±9.4	2,000	246	IHD and stroke
Wildisen L, (2020)	Europe, multicenter	heart failure, high CVD risk	Subclinical	Subclinical: 83.8±5.3 Control: 83.5±6.2	3,876	264	HF and CV mortality

≥65 yr	1.57(2.30–2.66)	-	2
CVD risk group			
Increase	-	-	-
Decrease	1.30 (2.00–2.57)	67.2	8

Heart ischemia and hyperthyroidism

A pooled analysis of four high-quality studies was performed for the association between IHD and overt hyperthyroidism (Figure 2). Our study showed negligible heterogeneity (I = 0%, P = 0.70) and solid proof of a relationship between unmistakable hyperthyroidism and IHD (HR 1.22; 95% CI 1.02 to 1.18). Subgroup analysis in view old enough and cardiovascular risk was impractical (Table 2).This is because all relevant studies included him under the age of 65 and at low cardiovascular risk. Iodine intake status-based subgroup analysis revealed that areas with high iodine levels had a higher risk of IHD.

Table 3: Subgroup analysis of relationship between subclinical hyperthyroidism and risk of cardiovascular occasions

Subgroup	Pooled HR (95% CI)	I2, %	No. of studies
Ischemic heart disease			
Age group			
<65 yr	1.36 (1.05–2.62)	0	8
≥65 yr	1.26 (0.77–2.44)	0	5
CVD risk group			
Increase	1.23 (0.89–2.66)	15.6	5
Decrease	1.33 (2.03–2.54)	0	8
Stroke			
Age group			
<65 yr	1.34(0.83–1.80)	0	3
≥65 yr	1.23 (0.24–8.82)	57.5	4
CVD risk group			
Increase (with A-fib)	1.57 (0.23–5.93)	92	3
Decrease	1.25 (0.78–1.44)	0	4
Heart failure			
Age group		)	
<65 yr	1.43 (0.75–1.78)	-	2
≥65 yr	1.30 (0.36–6.43)	84.3	4
CVD risk group			
Increase	1.62 (0.65–4.45)	95.8	3
Decrease	1.35 (0.72–2.81)	23.8	3
CV mortality			
Age group			
<65 yr	1.25 (0.72–1.83)	76	7
≥65 yr	0.88 (0.68–2.34)	29.6	10
CVD risk group			
Increase	1.35 (0.30–2.82)	83.8	6
Decrease	1.35 (2.00–2.68)	25.2	11

Hyperthyroidism and CV mortality

Plain hyperthyroidism was linked to increased CV mortality with significant heterogeneity, according to seven studies (Fig. 2). The subgroup study also revealed increased CV mortality risk in areas with sufficient iodine.

Subclinical hyperthyroidism and directional heterogeneity in CV mortality did not seen to be significantly correlated. Subgroup analyses revealed no discernible differences in the results (Table 3).



Figure 2: Plots in the forest for hyperthyroidism and the possibility of cardiovascular (CV) death.

DISCUSSION

Utilizing information from 37 cohort studies, we played out a momentum meta-analysis to look at the connection among hyperthyroidism and IHD, stroke, cardiovascular illness, and cardiovascular mortality (Kwon H, 2018). We observed that clear hyperthyroidism was related with an expanded risk of IHD, stroke, and cardiovascular demise, while subclinical hyperthyroidism was related with an expanded risk of IHD.

Obviously, hyperthyroidism has a 20% higher risk of cardiovascular passing contrasted and euthyroid controls or everyone, with expanded risk of IHD and stroke being the significant reasons for cardiovascular demise (la Cour JL, 2015). It appears this is supposedly the first meta-analysis to analyze the connection among IHD and stroke and unmistakable hyperthyroidism. There are a few potential clarifications for why individuals with hyperthyroidism are bound to encounter atherosclerotic occasions. Elevated degrees of thyroid chemical are perceived to be related with major procoagulant proteins, including von Will mark factor, fibrinogen, factors VIII and IX, and endothelial harm. As indicated by a new report by Bano et al., levels of free thyroxin might be essentially related with atherosclerotic occasions autonomously of regular cardiovascular risk factors (Langen VL, 2018). Given the connection among hyperthyroidism and stroke, a few studies have speculated that atrial fibrillation because of hyperthyroidism might expand the risk of thromboembolic occasions like ischemic stroke. I'm here. Subgroup analysis via cardiovascular risk showed a measurably huge relationship between clear hyperthyroidism and stroke just in those without atrial fibrillation. Consequently, it is improbable that AF will affect the raised risk of stroke in unambiguous hyperthyroidism; notwithstanding, it is anticipated that further late cohort studies will affirm this statement (Lillevang-Johansen M, 2019). Patients with hyperthyroidism who were more established than 65 years of age had a higher risk of stroke in the subgroup analysis by age bunch. In any case, there were not many studies that specifically examined hyperthyroid individuals above the age of 65, making it impossible to determine whether age-related risks were unique.

CONCLUSION

Our meta-analysis found a credible link between subclinical hyperthyroidism and a heightened risk of CHD, CHD mortality, and overall mortality. It also found a logical link between subclinical hypothyroidism and a heightened risk of CHD mortality. Even though there are some confounders in this review, such as the affiliations found generally are much weaker, changed follow-up length, and determination predisposition were thought in many studies, we accept that the findings in this meta-analysis provide valuable information to collaborators with an interest in the outcomes of patients with subclinical thyroid brokenness. According to our meta-analysis, overt hyperthyroidism is associated with increased risk of IHD, stroke, and cardiovascular death, whereas subclinical hyperthyroidism is only associated with increased risk of IHD. Related the relationships uncovered in the current review have inevitably plagued those who lack some basic type of CVD. It is hoped that future studies using participant-specific data will make establishing the relationship between hyperthyroidism and the risk of cardiovascular events easier.

REFERENCES

1. Agbaht K, Gullu S. Adrenocortical reserves in hyperthyroidism. Endocrine. 2014; 45:136–43.
2. Berta E, Lengyel I, Halmi S, et al. Hypertension in Thyroid Disorders. Front Endocrinal (Lausanne) 2019; 10:482. 10.3389/fendo.2019.00482
3. Jabbar A, Pingitore A, Pearce SH, Zaman A, Iervasi G, Razvi S. Thyroid hormones and cardiovascular disease. Nat Rev Cardiol 2017; 14:39-55.
4. Kim HJ, Kang T, Kang MJ, Ahn HS, Sohn SY. Incidence and mortality of myocardial infarction and stroke in patients with hyperthyroidism: a nationwide cohort study in Korea. Thyroid 2020; 30:955-65.
5. Kwon H, Jung JH, Han KD, Park YG, Cho JH, Lee DY, et al. Prevalence and annual incidence of thyroid disease in Korea from 2006 to 2015: a nationwide population-based cohort study. Endocrinol Metab (Seoul) 2018; 33:260-7.
6. la Cour JL, Jensen LT, Vej-Hansen A, Nygaard B. Radioiodine therapy increases the risk of cerebrovascular events in hyperthyroid and euthyroid patients. Eur J Endocrinol 2015; 172:771-8.
7. Langen VL, Niiranen TJ, Puukka P, Lehtonen AO, Hernesniemi JA, Sundvall J, et al. Thyroid-stimulating hormone and risk of sudden cardiac death, total mortality and cardiovascular morbidity. Clin Endocrinol (Oxf) 2018; 88:105-13.
8. Lillevang-Johansen M, Abrahamsen B, Jorgensen HL, et al. Duration of Hyperthyroidism and Lack of Sufficient Treatment Are Associated with Increased Cardiovascular Risk. Thyroid 2019; 29:332-40. 10.1089/thy.2018.0320
9. Martin SS, Daya N, Lutsey PL, Matsushita K, Fretz A, McEvoy JW, et al. Thyroid function, cardiovascular risk factors, and incident atherosclerotic cardiovascular disease: the Atherosclerosis Risk in Communities (ARIC) Study. J Clin Endocrinol Metab 2017; 102:3306-15.
10. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj. 2021; 372:n71.
11. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of

Thyrotoxicosis. Thyroid 2016; 26:1343-421. 10.1089/thy.2016.0229
12. Ryodi E, Metso S, Huhtala H, Valimaki M, Auvinen A, Jaatinen P. Cardiovascular morbidity and mortality after treatment of hyperthyroidism with either radioactive iodine or thyroidectomy. Thyroid 2018; 28:1111-20.
13. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Metaanalysis of observational studies in epidemiology: a proposal for reporting. Metaanalysis Of Observational Studies in Epidemiology (MOOSE) group. Jama. 2000; 283:2008–12.
14. Wartofsky L. Hyperthyroidism. In: Diseases NIoDaDaK. Editor. NIDDK. Bethesda, MD: National Endocrine and Metabolic Diseases Information Service, 2012.
15. Wildisen L, Del Giovane C, Moutzouri E, Beglinger S, Syrogiannouli L, Collet TH, et al. An individual participant data analysis of prospective cohort studies on the association between subclinical thyroid dysfunction and depressive symptoms. Sci Rep. 2020; 10:19111.